Literature DB >> 28396056

Connecting the Metabolic and Immune Responses to Cancer.

Thomas R Flint1, Douglas T Fearon2, Tobias Janowitz3.   

Abstract

Separate research fields have advanced our understanding of, on the one hand, cancer immunology and, on the other hand, cachexia, the fatal tumor-induced wasting syndrome. A link between the host's immune and metabolic responses to cancer remained unexplored. Emerging work in preclinical models of colorectal and pancreatic cancer has unveiled tumor-induced reprogramming of liver metabolism in cachexia that leads to suppression of antitumor immunity and failure of immunotherapy. As research efforts in metabolism and immunology in cancer are rapidly expanding, it is timely to discuss the metabolic and immunological determinants of the cancer-host interaction. We also present the hypothesis that the convergence of host metabolism and antitumor immunity may offer a platform for biomarker-driven investigations of new combination therapies.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  cachexia; caloric deficiency; cancer immunotherapy; glucocorticoids; hepatic metabolism; interleukin-6

Mesh:

Year:  2017        PMID: 28396056     DOI: 10.1016/j.molmed.2017.03.001

Source DB:  PubMed          Journal:  Trends Mol Med        ISSN: 1471-4914            Impact factor:   11.951


  23 in total

1.  Effect of Prognostic Nutrition Index in Gastric or Gastro-oesophageal Junction Cancer Patients Undergoing Nivolumab Monotherapy.

Authors:  Takashi Oshima; Hayato Watanabe; Takanobu Yamada; Keisuke Komori; Kentaro Hara; Kazuki Kano; Kosuke Takahashi; Yuta Kumazu; Hirohito Fujikawa; Masakatsu Numata; Toru Aoyama; Hiroshi Tamagawa; Yasuhiro Inokuchi; Nozomu Machida; Manabu Shiozawa; Norio Yukawa; Soichiro Morinaga; Yasushi Rino; Munetaka Masuda; Takashi Ogata
Journal:  In Vivo       Date:  2021 Jan-Feb       Impact factor: 2.155

2.  Postdiagnosis Loss of Skeletal Muscle, but Not Adipose Tissue, Is Associated with Shorter Survival of Patients with Advanced Pancreatic Cancer.

Authors:  Ana Babic; Michael H Rosenthal; Gloria M Petersen; Brian M Wolpin; William R Bamlet; Naoki Takahashi; Motokazu Sugimoto; Laura V Danai; Vicente Morales-Oyarvide; Natalia Khalaf; Richard F Dunne; Lauren K Brais; Marisa W Welch; Caitlin L Zellers; Courtney Dennis; Nader Rifai; Carla M Prado; Bette Caan; Tilak K Sundaresan; Jeffrey A Meyerhardt; Matthew H Kulke; Clary B Clish; Kimmie Ng; Matthew G Vander Heiden
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2019-09-18       Impact factor: 4.254

3.  TET2-dependent IL-6 induction mediated by the tumor microenvironment promotes tumor metastasis in osteosarcoma.

Authors:  Hitoshi Itoh; Tsuyoshi Kadomatsu; Hironori Tanoue; Masaki Yugami; Keishi Miyata; Motoyoshi Endo; Jun Morinaga; Eisuke Kobayashi; Takeshi Miyamoto; Ryoma Kurahashi; Kazutoyo Terada; Hiroshi Mizuta; Yuichi Oike
Journal:  Oncogene       Date:  2018-03-08       Impact factor: 9.867

4.  Impact of weight loss on treatment with PD-1/PD-L1 inhibitors plus chemotherapy in advanced non-small-cell lung cancer.

Authors:  Taichi Miyawaki; Tateaki Naito; Michitoshi Yabe; Hiroaki Kodama; Naoya Nishioka; Eriko Miyawaki; Nobuaki Mamesaya; Haruki Kobayashi; Shota Omori; Kazushige Wakuda; Akira Ono; Hirotsugu Kenmotsu; Haruyasu Murakami; Keita Mori; Hideyuki Harada; Kazuhisa Takahashi; Toshiaki Takahashi
Journal:  Support Care Cancer       Date:  2021-09-22       Impact factor: 3.359

5.  Cachectic Cancer Patients: Immune to Checkpoint Inhibitor Therapy?

Authors:  Christopher C Coss; Steven K Clinton; Mitch A Phelps
Journal:  Clin Cancer Res       Date:  2018-07-17       Impact factor: 12.531

Review 6.  Cancer-Mediated Muscle Cachexia: Etiology and Clinical Management.

Authors:  Thomas Siff; Parash Parajuli; Mohammed S Razzaque; Azeddine Atfi
Journal:  Trends Endocrinol Metab       Date:  2021-04-19       Impact factor: 10.586

Review 7.  A molecular and preclinical comparison of the PD-1-targeted T-cell checkpoint inhibitors nivolumab and pembrolizumab.

Authors:  Petros Fessas; Hassal Lee; Shinji Ikemizu; Tobias Janowitz
Journal:  Semin Oncol       Date:  2017-07-04       Impact factor: 4.929

8.  Prognostic significance of cachexia in advanced non-small cell lung cancer patients treated with pembrolizumab.

Authors:  Hitomi Jo; Tatsuya Yoshida; Hidehito Horinouchi; Shigehiro Yagishita; Yuji Matsumoto; Yuki Shinno; Yusuke Okuma; Yasushi Goto; Noboru Yamamoto; Kazuhisa Takahashi; Noriko Motoi; Yuichiro Ohe
Journal:  Cancer Immunol Immunother       Date:  2021-06-27       Impact factor: 6.968

9.  Cancer Immunotherapy Trials Underutilize Immune Response Monitoring.

Authors:  Claire M Connell; Sophie E M Raby; Ian Beh; Thomas R Flint; Edward H Williams; Douglas T Fearon; Duncan I Jodrell; Tobias Janowitz
Journal:  Oncologist       Date:  2017-10-11

10.  The Warburg effect in human pancreatic cancer cells triggers cachexia in athymic mice carrying the cancer cells.

Authors:  Feng Wang; Hongyi Liu; Lijuan Hu; Yunfei Liu; Yijie Duan; Rui Cui; Wencong Tian
Journal:  BMC Cancer       Date:  2018-04-02       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.